Search
Tradipitant
go.drugbank.com/drugs/DB12580ApprovedInvestigational[A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion. … Tradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors.
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalIt is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. … Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen.
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaPeginesatide
go.drugbank.com/drugs/DB08894ApprovedWithdrawnChemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. … Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012.
Bexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigational[A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. … Its use is not recommended in patients with type 1 diabetes since it may increase their risk of diabetic ketoacidosis.[L44758]
Acetylcysteine
go.drugbank.com/drugs/DB06151ApprovedInvestigational[A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488]
Mixtures: AMINOSTERIL N-HEPA 500 ML SOLUSYON, N-ACETILCISTEÍNA MAS GUAYACOLATO DE GLICERILOSynonyms: N-AC, N-acetylcysteineSugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigational[L53333] In combination with platinum-based chemotherapy, sugemalimab is a first-line treatment indicated for adult populations with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR … The antibody has also been granted the Breakthrough Therapy Designation by the FDA to treat relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) and an orphan drug designation
Dolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigational[A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013. … [A7514] The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity.
Berotralstat
go.drugbank.com/drugs/DB15982ApprovedInvestigational[A225166] Berotralstat is strictly used to prevent, but not treat, these attacks.[L26656] Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. … [L26661] Berotralstat was approved by the European Commission on April 30, 2021 [L41965] and by Health Canada on June 06, 2022.
Synonyms: 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide, (+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochlorideAntrafenine
go.drugbank.com/drugs/DB01419ApprovedIt is not widely used as it has largely been replaced by newer drugs. … Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Non COX-2 selective NSAIDSOlmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigationalARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling. … [A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882]
Mixtures: OPENVAS CO, ALMETEC-COCategories: Agents Acting on the Renin-Angiotensin System